glp-1 news today pharma Giants Bet on Next-Generation Treatments to Sustain Growth A new weight-loss pill- Foundayo,

If your vial arrives without clear labeling, contact the pharmacy before using it

They are straightforward purchasing approaches that vendors openly support because higher volume means guaranteed revenue for them

Fourth - and most time-sensitive: the FDA published a proposed rule on April 30, 2026 proposing to exclude semaglutide and tirzepatide from the 503B Bulks List, with a public comment period closing June 29, 2026

WHO issues guidelines for GLP-1 receptor agonists in obesity The World Health Organization introduced guidelines to aid clinicians in the use of glucagon-like peptide-1 receptor agonists to treat obesity